Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients

2021 ◽  
Vol 45 (5) ◽  
pp. 101583 ◽  
Author(s):  
Xinyi Cao ◽  
Zhao Cao ◽  
Chao Ou ◽  
Lei Zhang ◽  
Yanhua Chen ◽  
...  
2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Satoshi Nakayama ◽  
Naoya Murashima

Portal vein thrombosis is a major complication associated with liver cirrhosis. In cirrhotic patients, a decrease in procoagulant and anticoagulant factors and an unstable balance between them is observed, and a relative decrease in the activation of anticoagulant drivers is one of the main causes of portal vein thrombosis (PVT). Herein, we report a case of acute portal thrombosis associated with liver cirrhosis and treated with a recombinant form of soluble thrombomodulin (thrombomodulin alpha, TM-α) in combination with antithrombin III. TM-α was administered in accordance with the dosage and route of administration for disseminated intravascular coagulation therapy and resulted in dissolution of PVT with a gradual decrease in D-dimer levels. No adverse events were observed during the course of treatment. In the future, in addition to conventional anticoagulation therapy using heparin or antivitamin K drugs, novel therapies targeting protein C activation using a recombinant form of soluble thrombomodulin may play an important role in the treatment of acute PVT.


The Lancet ◽  
1997 ◽  
Vol 349 (9058) ◽  
pp. 1069 ◽  
Author(s):  
Franco Carmassi ◽  
Ferdinando De Negri ◽  
Marco Morale ◽  
Laura Ferrini

2010 ◽  
Vol 251 (1) ◽  
pp. 76-83 ◽  
Author(s):  
Hirofumi Kawanaka ◽  
Tomohiko Akahoshi ◽  
Nao Kinjo ◽  
Kozou Konishi ◽  
Daisuke Yoshida ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document